文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

电灼增强型腔道金属支架行EUS引导胆管十二指肠吻合术治疗恶性远端胆道梗阻:英国与爱尔兰多中心合作研究

EUS-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing metal stents in patients with malignant distal biliary obstruction: multicenter collaboration from the United Kingdom and Ireland.
PubMed 文献 · Gastrointest Endosc · 2021-10-09

技术成功率为90.8%,临床成功率为94.8%(92/97),不良事件率为17.5%,初次技术成功后需胆道再干预者占8.3%。

要点

  • EUS-CDD联合EC-LAMS在ERCP不可行或失败时技术成功率达90.8%
  • 临床成功定义为14天内血清胆红素降至原值≤50%,达94.8%
  • 不良事件率17.5%,多数可通过保守或内镜治疗处理

核心结论

  • 在区域肝胆胰网络的三级中心,对ERCP不可行或失败的恶性远端胆道梗阻患者,EUS-CDD联合EC-LAMS是有效的引流方法。
  • 发生技术失败或不良事件时,多数患者可通过保守或内镜治疗处理。

研究设计与样本

  • 回顾性研究,纳入英国和爱尔兰8家三级中心2016年9月至2020年11月连续接受EUS-CDD联合EC-LAMS的恶性远端胆道梗阻患者。
  • 117例患者的中位随访期为70天(四分位距169;范围3-869),随访结束时23例(19.2%)存活,3例失访。

主要发现

  • 临床成功率(14天内血清胆红素降至原值≤50%)为94.8%(92/97)。
  • 不良事件率为17.5%(21例)。
  • 初次技术成功后需胆道再干预者占8.3%(9例)。

关键数值与推荐

  • 临床成功定义为14天内血清胆红素降至原值≤50%。

临床怎么用

  • 对于恶性远端胆道梗阻且ERCP不可行或失败的患者,可考虑EUS-CDD联合EC-LAMS作为胆道引流选择。
  • 术后需关注不良事件,多数可通过保守或内镜治疗管理。

局限性

  • 回顾性研究设计。
  • 随访时间有限,中位随访70天,随访结束时仅23例(19.2%)存活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: EUS-guided choledochoduodenostomy (EUS-CDD) with an electrocautery-enhanced lumen-apposing metal stent (EC-LAMS) has emerged as a viable method of establishing biliary drainage in patients with malignant distal biliary obstruction (MDBO). Our aim was to assess the efficacy, safety, and outcomes in patients with MDBO who underwent EUS-CDD with an EC-LAMS. METHODS: A retrospective review of consecutive patients with MDBO who underwent EUS-CDD with EC-LAMSs at 8 tertiary institutions across the United Kingdom and Ireland between September 2016 and November 2020 was undertaken. RESULTS: One hundred twenty patients (55% men) with a median age of 73 years (interquartile range, 17; range, 43-94) were included. The median follow-up period in 117 patients was 70 days (interquartile range, 169; range, 3-869), and 23 patients (19.2%) were alive at the end of the follow-up. Three patients were lost to follow-up. Technical success was achieved in 109 patients (90.8%). Clinical success (reduction of serum bilirubin to ≤50% of original value within 14 days) was achieved in 94.8% of patients (92/97). The adverse event rate was 17.5% (n = 21). Biliary reintervention after initial technical success was required in 9 patients (8.3%). CONCLUSIONS: EUS-CDD with EC-LAMSs at tertiary institutions within a regional hepatopancreatobiliary network for treatment of MDBO was effective in those where ERCP was not possible or was unsuccessful. When technical failures or adverse events occur, most patients can be managed with conservative or endoscopic therapy.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. On W, Paranandi B, Smith AM, et al. EUS-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing metal stents in patients with malignant distal biliary obstruction: multicenter collaboration from the United Kingdom and Ireland. Gastrointest Endosc. 2021. PMID: 34637805. doi:10.1016/j.gie.2021.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。